Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

For Lexicon Pharmaceuticals, No News Remains Bad News

The frustrating wait for the key driver at Lexicon Pharmaceuticals (NASDAQ:LXRX) - a clinical development and marketing partner for LX4211 - goes on. While management spent a lot of time on its earnings call reviewing the positive data and commercial opportunity in Type 1 diabetes, this was all pretty well known going into the call. Management believes it can go into Phase III development of LX4211 in Type 1 diabetes on its own, but these shares are likely stuck unless and until a partner emerges.

New Leadership, Old Problem

Lexicon announced a new CEO last month, naming Lionel Coats, the former head of Eisai's U.S. operations to the role. Mr. Coats does bring some relevant M&A experience...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details